Novel Prognostic Biomarkers for HCC Progression in Egyptian Patients

Abstract

Objectives: To evaluate values of Cyclin D and Cdk4 in HCC, hepatitis diseases and healthy controls, their clinicoradiological correlations and prognosis of HCC.

Methods: Group 1: 50 patients with HCC, Group 2: 50 patients with hepatitis diseases and Group 3: 30 healthy controls were enrolled. All patients were positive for hepatitis C virus (HCV) antibody and confirmed by HCV RNA. Calculation of Barcelona Clinic Liver Cancer (BCLC) staging system, MELD and Child-Pugh scores. mRNA for cyclin D1 and Cdk4 were analyzed by quantitative RT-PCR.

Results: The mean Cyclin D1 and Cdk4 values were higher in HCC group compared with the other two groups (p value = 0.001). In HCC group, the mean Cdk4 and cyclin D1 values were significantly higher among patients with multiple hepatic focal lesion (HFL) (p value = 0.0001, 0.003 respectively) compared with those with single lesion. A significant correlation between size of HFL, alpha-Fetoprotein (AFP) and mean Cdk4 value (p value = 0.028, 0.0001 respectively).

Conclusion: Significant values of cyclin D1 and Cdk4 in HCC, compared to normal and hepatitis diseases, correlated to the number, size of HFL and AFP level. Thus, the assessment of cyclin D1 and Cdk4 may provide a novel strategy for prognostication and targeted therapy of HCC.

Keywords: Hepatocellular carcinoma; Cyclin D1; Cdk4

Abbreviations: HCC: Hepatocellular Carcinoma; BCLC: Barcelona Clinic Liver Cancer; CLIP: Cancer of the Liver Italian Program; GETCH: Groupe d’Etude Et De Traitement Du Carcinome Hepatocellulaire; JIS: Japan Integrated Staging

Introduction

Hepatocellular carcinoma (HCC) is ranked as the fifth most common cancer worldwide [1], and the third most common cause of cancer related death worldwide [2]. Prognosis and survival estimation for HCC patients is a challenging issue not only because the extent of liver dysfunction has a key impact on survival more than the tumor itself but also due to the unique geographic characteristics of the disease. Therefore, over the years multidimensional staging systems including both the extension of tumor and liver function parameters (with general health variables included) have been developed: Okuda[3], Barcelona Clinic Liver Cancer (BCLC) [4], Cancer of the Liver Italian Program (CLIP) [5], Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire (GETCH) [6] and Japan Integrated Staging (JIS) [7].

Cyclin D1 and its catalytic partner CDK4 are known to play an important role in the G1/S checkpoint of the cell cycle. The activity of CDKs is negatively regulated by the cyclin-dependent kinase inhibitors (CDKIs) p16 and p27 which avert excessive cell replication [8-10]. CDK4 and cyclin D1 complex has been strongly implicated in the control of cell proliferation and prognoses in human malignancies. Overexpression of CDK4 and cyclin D1 has been reported in many cancers. Correlations between cyclin D1 overexpression and the prognosis of colorectal cancer [11,12], cell cancers of the urinary bladder [13] varian cancers [14], breast cancer [15], non-small cell lung cancer [16,17], and oesophageal cancer [18] have been reported. Moreover, an association between cyclin D1 status and the recurrence of head and neck squamous cell carcinoma [19-21], and survival has also been reported [22-26].

Since malignant transformations may occur as a result of alterations in the genes that directly control the cell cycle and mitosis, identification of new useful prognostic molecular markers (cell-cycle regulators) for HCC is required to improve the accuracy of predicting tumor behavior. The aims of this study is to determine the serum level of Cyclin D1 and Cdk4 in HCC patients and in benign liver conditions, to correlate them with some clinical and radiological HCC criteria and to investigate the prognostic importance of these markers by the potential correlation between them and the BCLC prognostic system.
Patients and Methods

This is a prospective cross sectional study including three age-matched groups; Group 1: 50 with HCC, Group 2: 50 patients with liver diseases (25 liver cirrhosis and 25 chronic hepatitis C). Patients were randomly recruited from the inpatient section and outpatient clinic of tropical medicine, gastroenterology and internal medicine departments, Assiut University. Group 3: included 30 healthy controls (volunteers).

Histological and/or AASLD radiological criteria [27] or the diagnosis of HCC was used for inclusion of HCC patients. Patients who had undergone any interventional treatment for HCC were excluded. The diagnosis of chronic hepatitis C was based on standard serological assay results (positive HCV antibody by the third generation enzyme-linked immuno sorbent assay, with infection confirmed by detection of circulating HCV RNA by polymerase chain reaction using the Amplicor HCV assay) and abnormal serum aminotransferase level for at least 6 months. The diagnosis of liver cirrhosis was made dependent on typical clinical signs, laboratory and on unequivocal radiological signs.

All baseline clinical and tumor parameters necessary to calculate the BCLC staging system were obtained.

Cyclin D1 and Cdk4 mRNA analysis by quantitative real-time RT-PCR

**Total RNA isolation:** Total RNA was isolated with RNA easy Mini Kit (Qiagen) and further analyzed for quantity and quality with Beckman dual spectrophotometer (USA). The RNA integrity and the GAPDH- RNA (house keeping gene) ratio were used as the quality control.

**Quantitative Reverse transcriptase PCR (QRT–PCR):** The mRNA expression level was quantified by qRT–PCR (Real time PCR). 1000 ng of the total RNA from each sample were used for cDNA synthesis by reverse transcription using High capacity cDNA Reverse Transcriptase kit (Applied Biosystem, USA). The cDNA was subsequently amplified with the Syber Green I PCR Master Kit (Fermentas) in a 48-well plate using the Step One instrument (Applied Biosystem, USA) as follows: 10 minutes at 95 °C for enzyme activation followed by 40 cycles of 15 seconds at 95 °C, 20 seconds at 55 °C and 30 second at 72 °C for the amplification step. Changes in the expression of each target gene were normalized relative to the mean critical threshold (CT) values of GAPDH housekeeping gene by the ΔΔCt method. We used 1 μM of both primers specific for each target gene. Primers sequence and annealing temperature specific for each gene demonstrated in Table 1.

| Target Gene | Primer Sequence: 5' - 3' | Gene Bank Accession Number |
|-------------|--------------------------|---------------------------|
| Cyclin D1   | Forward: CTCCTCTCGGAGCATTT  | XM_006718653.1           |
|             | Reverse: CTTGACCAACCGCTCC   |                           |
| CDK4        | Forward: TCCAGGGTGGTCAAAAGGA  | XM_011531810.1           |
|             | Reverse: CGGTCCGTCCTTACCT    |                           |
| GAPDH       | Forward: CTCCTACTGGGCGCTGCCAAGGCT  | NT_009759.16           |
|             | Reverse: GTGCCACCTCGACAAGTGG |                           |

Statistical Analysis

Patients' data were analyzed using SPSS 17.0 for windows 7 (SPSS Inc, Chicago, IL, USA). Quantitative variables were expressed by mean and SD (Standard deviation) and the Qualitative variables were expressed by numbers (Frequency) and percent. Students T test and ANOVA Test were used to compare numerical variable. Pearson and Spearman's correlation were used to assess the correlation between each of CDK4 and cyclin D1 and other studied variables. Univariate and multivariate linear regression were used to investigate possible associations between each of Cdk4 and cyclin D1 and other studied variable. P value was considered to be significant if < 0.05.

Ethical Considerations

The study steps were explained to all participants and an informed consent was obtained. Patients' data was considered confidential. The research was conducted only by scientifically qualified and trained personnel. The project was submitted to and approved by the ethical committee of the faculty of medicine, Assuit University.

Results

The three studied groups;

**Group 1:** included 41(82%) males and 9(18%) females with mean ± SD age of 59.1±7.7 and

**Group 2:** included 38(76%) males and 12(24%) females with mean ± SD age of 55.3±5.7

**Group 3:** included 24(80%) males and 6 (20%) females with mean ± SD age of 55.8±6.3 with no statistical significant difference between them as regards both the age and sex.

The baseline demographic, clinical, and radiological data of HCC group are shown in Table 2. The means SD of AFP and MELD score were 153.2±131.7 IU/l and 13.4±4.9 respectively.

Citation: Abdelmoneim SS, Abdelkader NA, Sabry D, Wakiel HME, Sabry A, et al. (2015) Novel Prognostic Biomarkers for HCC Progression in Egyptian Patients. Gastroenterol Hepatol Open Access 3(2): 00077. DOI: 10.15406/ghoa.2015.03.00077
Table 2: Demographic, clinical and radiological data in HCC group.

|                        | Mean ±SD / Frequency |
|------------------------|-----------------------|
| Age                    | 59.1 ± 7.7            |
| Sex                    |                       |
| Male                   | 41 ± 7.7 / 83.7%      |
| Female                 | 9 ± 7.7 / 18%         |
| Performance            |                       |
| 0                      | 37 ± 7.7 / 75.5%      |
| 1                      | 10 ± 7.7 / 20.4%      |
| 2                      | 3 ± 7.7 / 6%          |
| Portal HTN             |                       |
| Yes                    | 40 ± 7.7 / 81.6%      |
| No                     | 10 ± 7.7 / 20%        |
| Encephalopathy         |                       |
| Yes                    | 9 ± 7.7 / 18%         |
| No                     | 41 ± 7.7 / 83.7%      |
| Ascites                |                       |
| Yes                    | 20 ± 7.7 / 40%        |
| No                     | 30 ± 7.7 / 61.2%      |
| PVT                    |                       |
| Yes                    | 13 ± 7.7 / 26%        |
| No                     | 37 ± 7.7 / 75.5%      |
| Type of PVT            |                       |
| Benign                 | 2 ± 7.7 / 16.7%       |
| Malignant              | 10 ± 7.7 / 83.3%      |
| Number of HFL          |                       |
| Single                 | 27 ± 7.7 / 55.1%      |
| Multiple               | 23 ± 7.7 / 46%        |
| Size of HFL            |                       |
| Small                  | 12 ± 7.7 / 24.5%      |
| Medium                 | 13 ± 7.7 / 26.5%      |
| Large                  | 25 ± 7.7 / 50%        |
| BCLC Stage             |                       |
| Stage 0                | 7 ± 7.7 / 14.3%       |
| Stage A                | 8 ± 7.7 / 16.3%       |
| Stage B                | 13 ± 7.7 / 26.5%      |
| Stage C                | 14 ± 7.7 / 28.6%      |
| Stage D                | 8 ± 7.7 / 16.3%       |
| Child Grade            |                       |
| Child A                | 17 ± 7.7 / 34.7%      |
| Child B                | 25 ± 7.7 / 51.0%      |
| Child C                | 8 ± 7.7 / 16.3%       |

Cyclin D1 and Cdk4 mean serum level results in the studied groups:

a. In group 1, HCC patients, the mean cyclin D1 value was 1.06 ± 0.35 and Cdk4 mean value was 2.63 ± 1.2.

b. In group 2: in chronic hepatitis C patients, the mean cyclin D1 value was 0.284 ± 0.042 and Cdk4 mean value was 0.945 ± 0.524. In patients with liver cirrhosis the mean cyclin D1 value was 0.547 ± 0.26 and Cdk4 mean value was 1.186 ± 0.95 with statistical significance difference (p value = 0.001).

c. In group 3, the control group, the mean cyclin D1 value was 0.026 ± 0.014 and mean Cdk4 value was 0.513 ± 0.367. In the HCC group there was a direct correlation between cyclin D1 mean value and Cdk4 mean value however it was not significant (r: 0.063, p value= 0.666).

Relation between the demographic, clinical, radiological data and mean cyclin D1 and Cdk4 in HCC group (Table 3)

There was no significant difference as regard mean Cdk4 or cyclin D1 level between males and females patients (p value = 0
Correlation between demographic, clinical and radiological data and mean cyclin D1 and Cdk4 in HCC group (Table 4)

There was a direct significant correlation between the size of HFL, alpha-Fetoprotein and Cdk4 level (p value= 0.028 and 0.0001 respectively); otherwise no significant correlation was detected.

Univariate analysis of factors affecting mean cyclin D1 and cdk4 in HCC group (Table 5)

Univariate analysis showed that the number of HFL was the significant factor affecting Cyclin D1 and Cdk4 levels, while alpha-Fetoprotein, BCLC Stage3 were significant factors affecting Cdk4 level.

Multivariate analysis of factors affecting mean cyclin D1 and Cdk4 in HCC group (Table 6)

After adjustment to other variables, multivariate analysis showed that the number of HFL was the significant factor affecting cyclin D1 and Cdk4 levels while alpha-Fetoprotein, and large size of HFL were significant factors affecting Cdk4 level.

Table 3: Relation between some clinical and radiological data and CDK4 and cyclin D1 in HCC group.

|                  | CDK4         | p value | Cyclin D1   | p value |
|------------------|--------------|---------|-------------|---------|
|                  | Mean ±SD     |         | Mean ±SD    |         |
| Sex              |              |         |             |         |
| Male             | 2.54 ±1.20   | .299*   | 1.06 ±.35   | .937*   |
| Female           | 3.04 ±1.34   |         | 1.07 ±.38   |         |
| BCLC             |              |         |             |         |
| Stage 0          | 1.85 ±.51    | .162**  | 1.00 ±.18   | .928**  |
| Stage A          | 2.32 ±.99    |         | 1.01 ±.21   |         |
| Stage B          | 2.96 ±1.30   |         | 1.06 ±.41   |         |
| Stage C          | 3.04 ±1.43   |         | 1.13 ±.43   |         |
| Stage D          | 2.29 ±1.03   |         | 1.08 ±.40   |         |
| Child Grade      |              |         |             |         |
| Child A          | 2.30 ±1.05   | .186**  | 1.00 ±.17   | .604**  |
| Child B          | 2.94 ±1.33   |         | 1.11 ±.43   |         |
| Child C          | 2.29 ±1.03   |         | 1.08 ±.40   |         |
| Number of HFL    |              |         |             |         |
| Single           | 2.07 ±.91    | .0001*  | .93 ±.19    | .003*   |
| Multiple         | 3.31 ±1.22   |         | 1.22 ±.44   |         |
| Size of HFL      |              |         |             |         |
| Small            | 2.12 ±.90    | .145**  | 1.00 ±.17   | .338**  |
| Medium           | 2.50 ±1.28   |         | 1.19 ±.45   |         |
| Large            | 2.95 ±1.27   |         | 1.03 ±.36   |         |

*student test, **ANOVA

Table 4: Correlations between some clinical, radiological and laboratory data and CDK4 and cyclin D1 in HCC group.

|                  | CDK4 | Cyclin D1 |
|------------------|------|-----------|
| Age              |      |           |
|                  | Correlation coefficient* | .157 | -.208 |
|                  | P    | .280      | .152 |
| Size of HFL      |      |           |
|                  | Correlation coefficient**| .314 | -.088 |
|                  | P    | .028      | .547 |
| BCLC Stage       |      |           |
|                  | Correlation coefficient**| .179 | .040 |
|                  | P    | .218      | .782 |
| Child Grade      |      |           |
|                  | Correlation coefficient**| .063 | .040 |
|                  | P    | .669      | .783 |
| Alpha-Fetoprotein|      |           |
|                  | Correlation coefficient**| .639 | .022 |
|                  | P    | .0001     | .882 |
| MELD Score       |      |           |
|                  | Correlation coefficient* | -.113 | .157 |
|                  | P    | .440      | .282 |

*Pearson correlation, **Spearman’s correlation
Table 5: Univariate analysis of factors affecting CDK4 and Cyclin D1.

|                      | CDK4  |                      | Cyclin D1 |                      |
|----------------------|-------|----------------------|-----------|----------------------|
|                      | Regression coefficient | P Value | 95% CI for Regression Coefficients | Regression coefficient | P Value | 95% CI for Regression Coefficients |
| Age                  | .025  | .280                 | -.021     | .071                 | -.010  | .152                 | -.023     | .004                 |
| Sex(female)          | .494  | .299                 | -.453     | 1.441               | .011   | .937                 | -.266     | .288                 |
| alpha-Fetoprotein    | .006  | .0001                | -1.602    | 3.891               | .000   | .574                 | -.001     | .001                 |
| MELD Score           | -.028 | .440                 | .04        | .008                | .011   | .282                 | -.009     | .032                 |
| BCLC Stage*          |       |                      |           |                     |        |                      |           |                     |
| Stage1               | .466  | .451                 | -.769     | 1.701               | .009   | .963                 | -.372     | .389                 |
| Stage2               | 1.111 | .052                 | -.008     | 2.230               | .064   | .711                 | -.281     | .408                 |
| Stage3               | 1.189 | .036                 | .084      | 2.293               | .129   | .448                 | -.211     | .470                 |
| Stage4               | .433  | .498                 | -.843     | 1.708               | .085   | .666                 | -.308     | .478                 |
| Child Grade**        |       |                      |           |                     |        |                      |           |                     |
| Grade B              | .636  | .099                 | -.123     | 1.396               | .112   | .322                 | -.113     | .338                 |
| Grade C              | -.017 | .975                 | -.102     | 1.068               | .087   | .589                 | -.235     | .409                 |
| Number of HFL (multiple) | 1.241 | .0001                | .630      | 1.853               | .290   | .003                 | .102      | .477                 |
| Size of HFL ***      |       |                      |           |                     |        |                      |           |                     |
| Medium               | .382  | .428                 | -.580     | 1.345               | .189   | .187                 | -.095     | .472                 |
| Large                | .828  | .056                 | -.022     | 1.677               | .032   | .799                 | -.219     | .282                 |

*stage 0 reference, **Child A reference, ***small size is reference

Table 6: Multivariate analysis of factors affecting CDK4 and Cyclin D1.

|                      | CDK4  |                      | Cyclin D1 |                      |
|----------------------|-------|----------------------|-----------|----------------------|
|                      | Regression Coefficient | P value | 95% CI for Regression Coefficients | Regression Coefficient | P value | 95% CI for Regression Coefficients |
| Age                  | .005  | .785                 | -.033     | .043                 | -.011  | .111                 | -.026     | .003                 |
| Sex(female)          | .002  | .997                 | -.863     | .867                 | -.075  | .639                 | -.398     | .247                 |
| alpha-Fetoprotein    | .006  | .0001                | .003      | .009                 | .001   | .254                 | .000      | .002                 |
| MELD Score           | -.082 | .056                 | -.165     | .002                 | .002   | .921                 | -.030     | .033                 |
| BCLC Stage*          |       |                      |           |                     |        |                      |           |                     |
| Stage1               | .552  | .399                 | -.761     | 1.864               | -.076  | .752                 | -.557     | .406                 |
| Stage2               | 1.043 | .178                 | -.496     | 2.582               | .041   | .883                 | -.523     | .605                 |
| Stage3               | .850  | .301                 | -.792     | 2.492               | -.052  | .861                 | -.651     | .547                 |
| Stage4               | .679  | .581                 | -.179     | 3.155               | .467   | .295                 | -.425     | 1.359                |
| Child Grade**        |       |                      |           |                     |        |                      |           |                     |
| Grade B              | .093  | .824                 | -.751     | .937                | -.102  | .513                 | -.417     | .212                 |
| Grade C              | 1.212 | .111                 | -.291     | 2.714               | -.056  | .842                 | -.616     | .504                 |
| Number of HFL (multiple) | 1.001 | .003                | .352      | 1.649               | .364   | .004                 | .122      | .606                 |
| Size of HFL ***      |       |                      |           |                     |        |                      |           |                     |
| Medium               | -.440 | .400                 | -1.488    | .608                | .189   | .333                 | -.202     | .579                 |
| Large                | -1.340| .028                | -2.530    | -1.150              | -.242  | .275                 | -.686     | .201                 |

*stage 0 reference, **Child A reference, ***small size is reference
Discussion

Deregulation in cell cycle-related kinase activities, specifically cyclin D1 and cyclin-Cdk4/Cdk6 complexes, is one of the most significant alterations in cancer cells. Although there is an increasing evidence that perturbation of cell cycle regulation is one of the important factors contributing to cancer, there have been few studies showing the relationship between cyclins and human HCC [28,29]. Here we investigated biochemical differences of mean cell cyclin D1 and Cdk4 mRNA values in controls, benign (chronic hepatitis C and liver cirrhosis) and malignant (HCC) liver diseases. We also investigated the relationship between these proteins and the clinicoradiological characteristics and BCLC staging of HCC.

In this study, cyclin D1 and Cdk4 mean serum levels were higher in HCC compared to healthy controls and benign liver diseases suggesting that an increase of cyclin D1/Cdk4 may be associated with the process of transition from hepatitis C-induced cirrhosis to HCC. These data appear to be consistent with the results of previous studies showing that cyclin D1 and Cdk4 increased proportionally with the development of HCC, especially in the transition process from chronic hepatitis to HCC [30]. Moreover, overexpression of cyclin D1 and Cdk4 also has been also shown in human cancers other than HCC [11-19].

HCC usually develops on top of chronic liver diseases such as chronic hepatitis and liver cirrhosis in which the hepatocytes are persistently regenerating following hepatic injury. This process helps to select cell clones with growth advantage that harbor disorder of cell cycle genes resulting in hepatocarcinogenesis.

However, this contradicts reports by Shian-Yang Peng & colleagues [31] who showed that cyclin D1 is downregulated in HCC. Moreover, Zhang and his colleagues reported that cyclin D1 genotype frequencies were similar in HCCs and controls and were not associated with susceptibility to develop HCC probably owing to the small sample size (97 HCCs and 35 controls) [32].

In consistence with [33], our study showed that the high mean level of Cyclin D1 correlated with a high mean level of Cdk4 in HCC patients, supporting the notion that Cyclin D1 and Cdk4 form a complex to promote HCC proliferation. Moreover, the overexpression of both cyclin D1 and Cdk4 was also reported in 65% liver tumors other than HCC [34]. Contradicting reports by Lu and his team demonstrated that the mRNA level of Cdk4 was up-regulated, while that of Cyclin D1 was down-regulated [35].

This study also revealed significantly higher mean Cdk4 and cyclin D1 levels among patients with multiple hepatic focal lesions compared to patients with single lesion. Thus, the enhancement of cyclin D1 and Cdk4 activities may play an important role in the growth of HCC. These cyclin and cyclin-dependent kinase (Cdk4) complexes are known to play a critical role in cell proliferation and differentiation [36].

In our study, direct significant correlations between the size of HFL, alpha-Fetoprotein level and Cdk4 value were detected which may reflect some prognostic importance. These findings were in concordance with other studies which reported high Cdk4 protein levels and kinase activities in poorly differentiated HCC [37] and tumor size and stage [35].

Univariate analysis of the level of cyclin D1 and Cdk4 with clinicoradiological parameters, and BCLC staging demonstrated that the high serum level of both correlates only with the multiple number of HFL (p =0.003 and 0.000 respectively) while alpha-Fetoprotein, BCLC Stage3 and large size HFL were significant factors correlating with Cdk4 level.

Finally, we want to emphasize that the activity of cell cycle-related kinases, namely cyclin D1 and Cdk4, were high in cirrhosis (preneoplastic stage) before the development of HCC, this activation appears to be an early event in hepatocarcinogenesis. These data suggest that hepatitis C virus-induced cirrhosis is a precancerous condition. In addition, the high serum levels of cyclin D1 and Cdk4 was shown to be related to the progression of HCC. Thus, the assessment of cyclin D1 and Cdk4 activities may provide a novel strategy for prognostication and targeted therapy of HCC.

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61(2): 69-90.
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, et al. (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18(3): 581-92.
3. Okuda K, Ohtsuji T, Obata H (1985) Natural History of Hepatocellular Carcinoma and Prognosis in Relation to Treatment. Study of 850 Patients. Cancer 56(4): 918-928.
4. Lovet JM, Bruccu C, Bruccu J (1999) Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification. Semin Liver Dis 19(3): 329-338.
5. The Cancer of the Liver Italian Program (CLIP) Investigators (1998) A New Prognostic System for Hepatocellular Carcinoma: A Retrospective Study of 435 Patients. Hepatology 28(3): 751-775.
6. Chevreau S, Trinchet JC, Mathieu D (1999) A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 31(1): 133-141.
7. Kurdo M, Chung H, Osaki Y (2003) Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 38(3): 207-215.
8. Coleman WB (2003) Mechanisms of human hepatocarcinogenesis. Curr Mol Med 3(6): 573-588.
9. Reitelsdon MA, Sun B, Satiroghu Tufan NL, Liu J, Pan L, et al. (2002) Genetic mechanisms of hepatocarcinogenesis. Oncogene 21(16): 2593-2604.
10. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, et al. (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84(5): 1361-1392.
11. Maeda K, Chung YS, Kang SM, Ogawa M, Onoda N, et al. (1997) Overexpression of cyclin D1 and p53 associated with disease recurrence in colorectal adenocarcinoma. Int J Cancer 74(5): 139-149.
12. Arber N, Hoibohsoh H, Moss SF, Sutter T, Zhang Y, et al. (1996) Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 110(3): 669-674.
13. Lewis RC, Bostick RM, Xie D, Deng Z, Wargovic MJ, et al. (2003) Polymorphism of cyclin D1 gene, CCND1, and risk for incident sporadic colorectal adenomas. Cancer Res 63(23): 8549-8553.
Novel Prognostic Biomarkers for HCC Progression in Egyptian Patients

14. Donnellan R, Chetty R (1998) Cyclin D1 and human neoplasia. J Clin Pathol Mol Pathol 51(1): 1-7.
15. Barbieri E, Cagnoli M, Ragni N, Pedulla F, Foglia G, et al. (1997) Expression of cyclin D1 correlates with malignancy in human ovarian tumours. Br J Cancer 75(9): 1263-1268.
16. Sutherland RL, Musgrove EA (2002) Cyclin D1 and mammary carcinoma: new insight from transgenic mouse models. Breast Cancer Res 4(1): 14-7.
17. Betticher DC, Heighway J, Thatcher N, Hasleton PS (1997) Abnormal expression of CCND1 and RB1 in resection margin epithelia of lung cancer patients. Br J Cancer 75(12): 1761-1768.
18. Yuan Q, Xu JY, Zhang J, He QC, Zhu J, et al. (2004) Expression and significance of cyclin D1, p27kip1 protein on bronchio alveolar carcinoma. J Zhejiang Univ Sci 5(2): 235-241.
19. Shintani M, Okazaki A, Masuda T, Kawada M, Ishizu M, et al. (2002) Overexpression of cyclin D1 contributes to malignant properties of esophageal tumor cells by increasing VEGF production and increasing Fas expression. Anticancer Res 22(2A): 639-647.
20. Ishikawa T, Furihata M, Ohtsuki Y, Ono H, et al. (1997) Ablent expression of p53 and retinoblastoma gene products in human esophageal squamous cell carcinoma. Int J Oncol 11(5): 1109-1114.
21. Itami A, Shimada Y, Watanabe G, Imamura M (1999) Prognostic value of p27kip1 and CyclinD1 expression in esophageal cancer. Oncology 57(4): 311-317.
22. Callender T, el-Naggar AK, Lee MS, Frankenthaler R, Luna MA, et al. (1994) PRAD1 (CCND1/cyclin D1) oncogene amplification in primary and head and neck squamous cell carcinoma. Cancer 74(1): 152-158.
23. Jones P, Fernandez P, Campo P (1994) PRAD1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Res 54(17): 4183-4187.
24. Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E, et al. (1995) Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinoma of the head and neck. Cancer Res 55(5): 975-978.
25. Fracchioni NS, Pruneri G, Pignatari L, Carboni N, Capuccio P, et al. (1997) Molecular and immunohistochemical analysis of the bcl-1/cyclin D1 gene in laryngeal squamous cell carcinomas: correlation of protein expression with lymph node metastases and advanced clinical stage. Cancer 79(6): 1114-1121.
26. Takes RP, Baatenburg de Jong RJ, Schuurink E, Litvinov SV, Hermans J, et al. (1998) Differences in expression of oncogenes and tumor suppressor genes in different sites of head and neck squamous cell. Anti-cancer Res 18(68): 4793-4800.
27. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Hepatology 42(5): 1208-1236.
28. Yamagata M, Masaki T, Okudaira T, Imai Y, Shina S, et al. (1999) Small hyperechoic nodules in chronic liver diseases include hepatocellular carcinoma with low cyclin D1 and Ki-67 expression. Hepatology 29(6): 1722-1729.
29. Chao Y, Shih YL, Chiu JH, Chau CY, Lui WY, et al. (1998) Overexpression of cyclin A but not Skp2 correlates with the tumor relapse of human hepatocellular carcinoma. Cancer Res 58(5): 985-990.
30. Masaki T, Shiratori Y, Rengifo W, Igarashi K, Matsumoto K, et al. (2000) Hepatocellular Carcinoma Cell Cycle: Study of Long-Evans Cinnamon Rats. Hepatology 32: 711-720.
31. Shian-Yang Peng, Sheng-Ping Chou, Hey-Chi Hsu (1998) Association of downregulation of cyclin D1 and of overexpression of cyclin E with p53 mutation, high tumor grade and poor prognosis in hepatocellular carcinoma. J Hepatol 29(2): 281-289
32. Zhang YJ, Chen SY, Chen CJ, Santella RM (2002) Polymorphisms in cyclinD1 gene and hepatocellular carcinoma. Mol carcinog 33(2): 125-129.
33. Che Y, Ye F, Xu R, Qing H, Wang X, et al. (2012) Co-expression of XIAP and Cyclin D1 Complex Correlates with a Poor Prognosis in Patients with Hepatocellular Carcinoma. Am J Pathol 180(5): 1798-1807.
34. Kim H, Ham EK, Kim YI, Chi JG, Lee HS, et al. (1998) expression of cyclin D1 and Gdf4 in tumorigenesis of sporadic hepatoblastomas. Cancer lett 131(2): 177-183.
35. Lu JW, Lin YM, Chang JG, Yeh KT, Chen RM, et al. (2013) Clinical implications of deregulated Cdk4 and Cyclin D1 expression in patients with human hepatocellular carcinoma. Med Oncol 30(1): 379-382.
36. Pardee AB (1989) G1 events and regulation of cell proliferation. Science 246(4930): 603-608.
37. Masaki T, Shiratori Y, Rengifo W, Igarashi K, Yamagata M, et al. (2003) Cyclin and cyclin dependent kinase: comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology 37(3): 534-543.